Tegaserod

Tegaserod was a landmark drug as the first 5-HT4 agonist approved for constipation-predominant irritable bowel syndrome, and it established the commercial viability of serotonergic prokinetics before highlighting their cardiovascular risks. Pharmacologically it is a 5-HT4 partial agonist, and binding studies at the human 5-HT4d receptor place it among the higher-affinity full-to-partial agonists whose activity reflects the receptor's active-state conformation ^[1].

A Cochrane systematic review of thirteen short-term placebo-controlled trials, conducted predominantly in women, found that tegaserod at 12 mg and 4 mg daily significantly increased the likelihood of global symptom relief in constipation-predominant irritable bowel syndrome and improved complete spontaneous bowel movements in chronic constipation, although the magnitude of benefit was modest and diarrhea was significantly more common than with placebo ^[2]. The clinical importance of these improvements was judged real but limited.

Tegaserod's development was shaped by safety concerns beyond the gut. It was associated in the postmarketing setting with ischemic colitis, part of a broader signal linking serotonergic irritable bowel therapies to ischemic events, and its 2007 withdrawal followed a pooled analysis suggesting excess cardiovascular ischemic events ^[3]. Its lack of full selectivity, with residual affinity for other 5-HT subtypes, is one reason newer agents such as velusetrag and prucalopride were designed to be more selective ^[3].

The dominant safety concerns with tegaserod are cardiovascular and vascular rather than the QT-prolongation problem that characterized cisapride. A pooled analysis suggested an excess of cardiovascular ischemic events, and postmarketing reports linked it to ischemic colitis, driving its 2007 market withdrawal; it was later reintroduced in the United States for women under 65 with constipation-predominant irritable bowel syndrome and without cardiovascular risk factors. The most common gastrointestinal adverse effects are diarrhea, headache, and abdominal pain. Careful cardiovascular risk assessment is central to any use.

Developed by Novartis under the code HTF-919, tegaserod was approved in the early 2000s as Zelnorm in the United States and Zelmac elsewhere, becoming the first 5-HT4 agonist indicated for constipation-predominant irritable bowel syndrome and later for chronic idiopathic constipation. In 2007 it was withdrawn after a retrospective analysis indicated an excess of cardiovascular ischemic events. Following reassessment of the data, the United States Food and Drug Administration reapproved it in 2019 for a restricted lower-risk population, making it one of the few withdrawn drugs to return to market.

Tegaserod occupies an important place in gastroenterology as the pioneering 5-HT4 agonist for irritable bowel syndrome and as a cautionary example of how incomplete receptor selectivity and vascular effects can undermine a serotonergic prokinetic. Its modest efficacy and complicated safety history mean it is now used selectively and is often contrasted with the cleaner profiles of later selective agents. It has no nootropic reputation, being a peripheral gut drug.